Charles River Laboratories

Healthcare · Diagnostics & Research

294.60$ +0.6% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Balance Sheet

Charles River Laboratories (CRL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 7,135 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CRL
Line item	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	234	363	411	571	701	800	2,627	2,538	2,558	2,806	2,160	2,204	1,733	1,558	1,586	1,645	1,885	2,068	2,712	2,930	3,856	4,693	5,491	7,024	7,603	8,195	7,528	7,135
Current Assets	97	90	120	210	278	371	510	419	501	608	618	596	553	426	485	553	607	559	657	827	898	1,021	1,201	1,274	1,439	1,609	1,403	1,447
Cash	25	15	33	58	123	182	208	115	175	225	244	183	179	69	110	156	160	118	118	164	195	238	228	245	234	277	195	214
Cash & Short-Term Investments	25	15	33	58	123	195	208	116	183	240	244	183	189	69	110	156	160	118	118	164	195	239	229	246	234	277	195	214
Receivables	33	36	46	98	94	112	202	171	203	214	210	197	193	185	203	221	258	270	364	430	472	514	618	650	752	780	721	709
Inventory	31	31	34	39	44	52	62	65	72	88	97	103	100	93	88	89	89	94	96	115	128	161	186	199	256	380	279	299
Property, Plant & Equipment	–	–	117	156	188	203	357	399	535	749	829	866	753	738	717	676	677	678	756	782	933	1,044	1,124	1,584	1,857	2,034	2,017	2,017
Goodwill	–	–	42	52	97	105	1,423	1,098	1,119	1,121	458	508	198	198	209	231	321	439	788	805	1,247	1,541	1,809	2,712	2,850	3,095	2,847	2,764
Intangible Assets	33	37	42	90	131	136	1,679	175	160	149	136	160	121	93	85	85	179	281	394	370	611	689	788	1,061	955	864	723	340
Total Liabilities	66	473	280	269	325	325	1,145	701	953	942	960	830	1,045	1,029	983	980	1,181	1,303	1,858	1,866	2,518	3,026	3,347	4,432	4,579	4,536	4,020	3,924
Current Liabilities	62	70	64	99	113	114	349	311	259	303	301	250	260	217	342	247	296	312	430	464	558	710	840	1,033	1,092	1,055	994	1,120
Short-Term Debt	0.4	3.5	0.4	0.9	67	61	81	36	25	25	35	50	31	15	139	21	32	17	27	31	35	59	75	36	50	441	114	61
Accounts Payable	12	9.3	11	14	13	19	29	29	28	37	41	31	31	34	31	32	34	37	68	78	66	111	122	198	206	169	140	149
Long-Term Debt	–	–	203	156	192	186	606	260	547	485	541	457	670	703	527	642	746	846	1,208	1,114	1,637	1,822	1,904	2,639	2,708	2,647	2,240	2,112
Shareholders' Equity	168	-110	117	290	357	465	1,473	1,827	1,595	1,860	1,199	1,374	687	527	601	641	672	733	837	1,045	1,317	1,635	2,115	2,535	2,976	3,597	3,462	3,165
Retained Earnings	156	-307	-319	-283	-233	-153	-63	79	23	178	-344	-238	-575	-466	-368	-265	-139	11	165	289	42	280	625	981	1,433	1,887	1,812	1,389
Shares Outstanding	10	20	32	44	47	49	56	72	70	69	67	66	63	51	48	48	48	48	48	49	49	50	51	51	51	51	52	50

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings